Investor Relations

ABOUT ALDEYRA

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the companyʼs lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The companyʼs clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Featured Video
Corporate Overview Presentation

Recent News

November 13, 2020
LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 13, 2020-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company’s senior management will participate in the following virtual investor conferences: Jefferies Virtual London Healthcare Conference : Aldeyra President and CEO ...
November 5, 2020
− Initiation of Phase 3 Objective Sign Trial in Dry Eye Disease Planned for the Fourth Quarter 2020 − Phase 2 Clinical Trials of ADX-629 in COVID-19, Atopic Asthma, and Psoriasis Expected to Initiate in the Fourth Quarter of 2020 − Top-line Results from the Phase 3 INVIGORATE Clinical Trial in ...
View All

Contact Us

Investor Relations Contact 

Scott Solomon
Sharon Merrill Associates
Senior Vice President
EMAIL: ALDX@investorrelations.com
PHONE: 857-383-2409

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video